Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04919980 · ClinicalTrials.gov registry record · NA
TVMR With the INNOVALVE System Trial - Early Feasibility Study
A NA study of Mitral Valve Regurgitation (Degenerative or Functional), sponsored by Edwards Lifesciences.
- Recruiting
- Registry status
- NA
- Development phase
- 65
- Enrollment target
- 17
- Study locations
NCT04919980 is a NA study of Mitral Valve Regurgitation (Degenerative or Functional) that is actively recruiting participants, run by Edwards Lifesciences. The registered enrollment target is 65 participants. The trial reports 17 study locations across 13 states.
The verdict
NCT04919980, a NA study of Mitral Valve Regurgitation (Degenerative or Functional), is actively recruiting participants, sponsored by Edwards Lifesciences.
- RECRUITING
- Registry status
- NA
- Development phase
- 65 participants
- Enrollment target
- 17
- Study locations
Study Summary
Study to evaluate the safety and performance of the INNOVALVE system
Conditions Studied
Interventions
- DEVICE INNOVALVE system
Study Locations (17)
New York
- Northwell Health - Manhasset
- Cornell - New York
- NewYork-Presbyterian / Columbia University - New York
Ohio
- Cleveland Clinic - Cleveland
- OhioHealth Research Institute - Columbus
Tennessee
- Vanderbilt University Medical Center - Nashville
- Ascension Saint Thomas - Nashville
California
- Cedars-Sinai - Los Angeles
Florida
- Naples Comprehensive Health - Naples
Georgia
- Piedmont Heart Institute - Atlanta
Illinois
- Northwestern - Chicago
Michigan
- University of Michigan Hospital and Health Systems - Ann Arbor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 65 participants |
| Start Date | 2022-09-01 |
| Est. Completion | 2031-07-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04919980
The ClinicalTrials.gov registry entry for NCT04919980 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 65 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Edwards Lifesciences, which has 57 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Mitral Valve Regurgitation (Degenerative or Functional) appearing as the primary indexed condition, and to 1 intervention - of which INNOVALVE system is the first listed.
NCT04919980 reports 17 study locations spanning 13 distinct geographic areas - top geographies include New York, Ohio, Tennessee.
Frequently Asked Questions
What is clinical trial NCT04919980 about?
NCT04919980 is a clinical study titled "TVMR With the INNOVALVE System Trial - Early Feasibility Study". Study to evaluate the safety and performance of the INNOVALVE system
What is the current status of trial NCT04919980?
This trial is currently recruiting. It is a NA study. The enrollment target is 65 participants. The study started on 2022-09-01. Estimated completion is 2031-07-01.
What conditions does trial NCT04919980 study?
This clinical trial studies the following conditions: Mitral Valve Regurgitation (Degenerative or Functional).
What interventions are being tested in trial NCT04919980?
The interventions under investigation include: INNOVALVE system (DEVICE).
Who is sponsoring clinical trial NCT04919980?
This trial is sponsored by Edwards Lifesciences, which has 57 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04919980 being conducted?
This trial has 17 study locations across California, Florida, Georgia, Illinois, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Mitral Valve Regurgitation (Degenerative or Functional)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.